{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:07:40Z","timestamp":1786118860488,"version":"build-2736575974"},"reference-count":65,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Clinics of North America"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.suc.2026.03.008","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T19:58:35Z","timestamp":1779911915000},"page":"603-617","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genetics and Screening in Prostate Cancer"],"prefix":"10.1016","volume":"106","author":[{"given":"Joseph G.R.","family":"Partuzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Mora-Garijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.suc.2026.03.008_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.56825","article-title":"Trends in prostate cancer incidence and mortality rates","volume":"8","author":"Van Blarigan","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.suc.2026.03.008_bib3","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00345-011-0801-1","article-title":"Familial risk and familial survival in prostate cancer","volume":"30","author":"Hemminki","year":"2012","journal-title":"World J Urol"},{"issue":"2","key":"10.1016\/j.suc.2026.03.008_bib4","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1056\/NEJM200007133430201","article-title":"Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland","volume":"343","author":"Lichtenstein","year":"2000","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.suc.2026.03.008_bib5","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1158\/1055-9965.EPI-13-0568","article-title":"The heritability of prostate cancer in the Nordic Twin Study of Cancer","volume":"23","author":"Hjelmborg","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"10.1016\/j.suc.2026.03.008_bib6","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jama.2015.17703","article-title":"Familial risk and heritability of cancer among twins in nordic countries","volume":"315","author":"Mucci","year":"2016","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.suc.2026.03.008_bib7","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1086\/316916","article-title":"Genetics of prostate cancer: too many loci, too few genes","volume":"67","author":"Ostrander","year":"2000","journal-title":"Am J Hum Genet"},{"issue":"14","key":"10.1016\/j.suc.2026.03.008_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411418","article-title":"DNA damage repair pathways in prostate cancer: a narrative review of molecular mechanisms, emerging biomarkers and therapeutic targets in precision oncology","volume":"24","author":"Grypari","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"Suppl 1","key":"10.1016\/j.suc.2026.03.008_bib9","first-page":"S3","article-title":"Germline genetics of prostate cancer","volume":"82","author":"Khan","year":"2022","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.suc.2026.03.008_bib10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.eururo.2019.08.025","article-title":"Prostate cancer risks for Male BRCA1 and BRCA2 mutation carriers: a prospective cohort study","volume":"77","author":"Nyberg","year":"2020","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.suc.2026.03.008_bib11","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/s41416-021-01675-5","article-title":"BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis","volume":"126","author":"Nyberg","year":"2022","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.suc.2026.03.008_bib12","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1001\/jamaoncol.2024.2185","article-title":"BRCA1, BRCA2, and associated cancer risks and management for Male patients: a review","volume":"10","author":"Cheng","year":"2024","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.suc.2026.03.008_bib13","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.eururo.2019.08.019","article-title":"Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers","volume":"76","author":"Page","year":"2019","journal-title":"Eur Urol"},{"issue":"14","key":"10.1016\/j.suc.2026.03.008_bib14","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer","volume":"31","author":"Castro","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.suc.2026.03.008_bib15","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.euo.2020.12.001","article-title":"Rare germline variants in ATM predispose to prostate cancer: a PRACTICAL consortium study","volume":"4","author":"Karlsson","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"10.1016\/j.suc.2026.03.008_bib16","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41416-021-01410-0","article-title":"PALB2 mutations and prostate cancer risk and survival","volume":"125","author":"Woko\u0142orczyk","year":"2021","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.suc.2026.03.008_bib17","article-title":"Association of HOXB13 G84E with prostate cancer among 592,158 men","volume":"23","author":"Crawford","year":"2025","journal-title":"J Natl Compr Cancer Netw"},{"issue":"8","key":"10.1016\/j.suc.2026.03.008_bib18","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/pros.23505","article-title":"A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer","volume":"78","author":"Wu","year":"2018","journal-title":"Prostate"},{"issue":"20","key":"10.1016\/j.suc.2026.03.008_bib19","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1200\/JCO-25-00007","article-title":"Systemic therapy in patients with metastatic castration-resistant prostate cancer: ASCO guideline update","volume":"43","author":"Garje","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.suc.2026.03.008_bib20","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/bjc.2017.429","article-title":"Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition","volume":"118","author":"Mikropoulos","year":"2018","journal-title":"Br J Cancer"},{"issue":"14","key":"10.1016\/j.suc.2026.03.008_bib21","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1200\/JCO.23.02105","article-title":"Efficacy of Poly(ADP-ribose) polymerase inhibitors by individual genes in homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer: a US food and drug administration pooled analysis","volume":"42","author":"Fallah","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.suc.2026.03.008_bib22","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.eururo.2024.12.007","article-title":"Heterogeneity of the treatment effect with PARP inhibitors in metastatic castration-resistant prostate cancer: a living interactive systematic review and meta-analysis","volume":"87","author":"Naqvi","year":"2025","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.suc.2026.03.008_bib23","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1158\/1078-0432.CCR-24-1210","article-title":"Prevalence of mismatch repair deficiency in primary prostate cancer in a large prospective cohort","volume":"31","author":"McNevin","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.suc.2026.03.008_bib24","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.eururo.2018.10.009","article-title":"Clinical features and therapeutic outcomes in men with advanced prostate cancer and DNA mismatch repair gene mutations","volume":"75","author":"Antonarakis","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.suc.2026.03.008_bib25","series-title":"StatPearls [Internet]. Treasure Island (FL)","article-title":"Lynch syndrome (Hereditary Nonpolyposis Colorectal Cancer) [updated 2024 Jun 8]","author":"Bhattacharya","year":"2025"},{"issue":"14","key":"10.1016\/j.suc.2026.03.008_bib26","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1200\/JCO.2012.44.1238","article-title":"Elevated risk of prostate cancer among men with Lynch syndrome","volume":"31","author":"Raymond","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.suc.2026.03.008_bib27","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMra1701695","article-title":"Metastatic prostate cancer","volume":"378","author":"Sartor","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.suc.2026.03.008_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0233260","article-title":"Mismatch repair deficiency in metastatic prostate cancer: response to PD-1 blockade and standard therapies","volume":"15","author":"Graham","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.suc.2026.03.008_bib30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.19.02107","article-title":"Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-High\/Mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164","volume":"38","author":"Le","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.suc.2026.03.008_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.suc.2026.03.008_bib32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(19)30671-0","article-title":"Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial","volume":"21","author":"Geoerger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.suc.2026.03.008_bib33","unstructured":"National Comprehensive Cancer Network (NCCN). Genetic\/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, version 2.2026. NCCN Clinical Practice Guidelines in Oncology. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_bopp.pdf (Accessed November 25, 2025)."},{"key":"10.1016\/j.suc.2026.03.008_bib34","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.urology.2021.05.028","article-title":"Cribriform prostate cancer: clinical pathologic and molecular considerations","volume":"155","author":"Hesterberg","year":"2021","journal-title":"Urology"},{"issue":"7","key":"10.1016\/j.suc.2026.03.008_bib35","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1111\/his.14645","article-title":"Histopathological and genetic features of mismatch repair-deficient high-grade prostate cancer","volume":"80","author":"Wyvekens","year":"2022","journal-title":"Histopathology"},{"issue":"6","key":"10.1016\/j.suc.2026.03.008_bib36","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/bjc.2011.307","article-title":"Genetic architecture of prostate cancer in the Ashkenazi Jewish population","volume":"105","author":"Vijai","year":"2011","journal-title":"Br J Cancer"},{"issue":"20","key":"10.1016\/j.suc.2026.03.008_bib37","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1056\/NEJM199705153362001","article-title":"The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi jews","volume":"336","author":"Struewing","year":"1997","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.suc.2026.03.008_bib38","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/JU.0000000000004089","article-title":"Germline pathogenic variants identified in patients with genitourinary malignancies undergoing universal testing: a multisite single-institution prospective study","volume":"212","author":"Choudry","year":"2024","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.suc.2026.03.008_bib39","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.euo.2023.07.008","article-title":"Efficacy of National Comprehensive Cancer Network Guidelines in identifying pathogenic germline variants among unselected patients with prostate cancer: the PROCLAIM trial","volume":"6","author":"Shore","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"10.1016\/j.suc.2026.03.008_bib40","doi-asserted-by":"crossref","first-page":"e784","DOI":"10.1200\/OP.22.00634","article-title":"Racial differences in germline genetic testing for prostate cancer: a systematic review","volume":"19","author":"Briggs","year":"2023","journal-title":"JCO Oncol Pract"},{"issue":"6","key":"10.1016\/j.suc.2026.03.008_bib41","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1200\/OP-24-00626","article-title":"Implementation of universal germline genetic testing into standard of care for patients with prostate cancer: the time is now","volume":"21","author":"Shore","year":"2025","journal-title":"JCO Oncol Pract"},{"issue":"1","key":"10.1016\/j.suc.2026.03.008_bib42","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41588-020-00748-0","article-title":"Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction","volume":"53","author":"Conti","year":"2021","journal-title":"Nat Genet"},{"issue":"14","key":"10.1016\/j.suc.2026.03.008_bib43","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.3390\/cancers17142334","article-title":"The role of genomic scores in the management of prostate cancer patients: a comprehensive narrative review","volume":"17","author":"Viti","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.suc.2026.03.008_bib44","doi-asserted-by":"crossref","first-page":"316.e1","DOI":"10.1016\/j.clgc.2022.09.006","article-title":"How well do polygenic risk scores identify men at high risk for prostate cancer? Systematic review and meta-analysis","volume":"21","author":"Siltari","year":"2023","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"10.1016\/j.suc.2026.03.008_bib45","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/jnci\/djac199","article-title":"Polygenic risk of any, metastatic, and fatal prostate cancer in the Million Veteran Program","volume":"115","author":"Pagadala","year":"2023","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.suc.2026.03.008_bib46","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/s41467-021-21287-0","article-title":"Polygenic hazard score is associated with prostate cancer in multi-ethnic populations","volume":"12","author":"Huynh-Le","year":"2021","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.suc.2026.03.008_bib47","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1200\/JCO.22.01453","article-title":"CanRisk-Prostate: a comprehensive, externally validated risk model for the prediction of future prostate cancer","volume":"41","author":"Nyberg","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.suc.2026.03.008_bib48","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-74172-z","article-title":"Prostate cancer risk prediction using a polygenic risk score","volume":"10","author":"Sipeky","year":"2020","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.suc.2026.03.008_bib49","doi-asserted-by":"crossref","first-page":"515","DOI":"10.6004\/jnccn.2019.7307","article-title":"Germline and somatic mutations in prostate cancer for the clinician","volume":"17","author":"Cheng","year":"2019","journal-title":"J Natl Compr Cancer Netw"},{"issue":"10305","key":"10.1016\/j.suc.2026.03.008_bib50","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(21)00950-8","article-title":"Prostate cancer","volume":"398","author":"Sandhu","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.suc.2026.03.008_bib51","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-3-030-32656-2_3","article-title":"Genetic, environmental, and nuclear factors governing genomic rearrangements","volume":"1210","author":"Ramanand","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.suc.2026.03.008_bib52","article-title":"Repertoire and clinical hierarchy of AR locus alterations in castration-resistant prostate cancer","volume":"27","author":"Virtanen","year":"2025","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.suc.2026.03.008_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102226","article-title":"Evaluation of the prognostic role of TP53 gene mutations in prostate cancer outcome: a systematic review and meta-analysis","volume":"22","author":"Maddah","year":"2024","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"10.1016\/j.suc.2026.03.008_bib54","doi-asserted-by":"crossref","first-page":"8.e11","DOI":"10.1016\/j.urolonc.2021.06.024","article-title":"Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer","volume":"40","author":"Nientiedt","year":"2022","journal-title":"Urol Oncol"},{"issue":"6","key":"10.1016\/j.suc.2026.03.008_bib55","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1158\/1078-0432.CCR-18-1943","article-title":"TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer","volume":"25","author":"De Laere","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.suc.2026.03.008_bib56","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nrurol.2018.9","article-title":"Clinical implications of PTEN loss in prostate cancer","volume":"15","author":"Jamaspishvili","year":"2018","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.suc.2026.03.008_bib57","article-title":"Real-World overall survival and treatment patterns by PTEN status in metastatic castration-resistant prostate cancer","volume":"8","author":"Gupta","year":"2024","journal-title":"JCO Precis Oncol"},{"issue":"13","key":"10.1016\/j.suc.2026.03.008_bib58","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1200\/JCO.19.02768","article-title":"Molecular biomarkers in localized prostate cancer: ASCO guideline","volume":"38","author":"Eggener","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.suc.2026.03.008_bib59","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.eururo.2020.11.021","article-title":"A systematic review of the evidence for the decipher genomic classifier in prostate cancer","volume":"79","author":"Jairath","year":"2021","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.suc.2026.03.008_bib60","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ijrobp.2023.04.010","article-title":"Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Ooncology\/RTOG 0126 randomized phase 3 trial","volume":"117","author":"Spratt","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"15","key":"10.1016\/j.suc.2026.03.008_bib61","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1200\/JCO.20.02997","article-title":"Impact of a genomic test on treatment decision in a predominantly African American population with favorable-risk prostate cancer: a randomized trial","volume":"39","author":"Murphy","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.suc.2026.03.008_bib63","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1185\/03007995.2014.899208","article-title":"Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry","volume":"30","author":"Crawford","year":"2014","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"10.1016\/j.suc.2026.03.008_bib64","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.eururo.2024.06.019","article-title":"Meta-analysis of individual patient-level data for a multimodal artificial intelligence biomarker in high-risk prostate cancer: results from six NRG\/RTOG phase 3 randomized trials","volume":"86","author":"Spratt","year":"2024","journal-title":"Eur Urol"},{"issue":"32","key":"10.1016\/j.suc.2026.03.008_bib65","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1200\/JCO.24.00365","article-title":"Development and validation of an artificial intelligence digital pathology biomarker to predict benefit of long-term hormonal therapy and radiotherapy in men with high-risk prostate cancer across multiple phase III trials","volume":"43","author":"Armstrong","year":"2025","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.suc.2026.03.008_bib66","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.3390\/cancers17152589","article-title":"Circulating tumor DNA in prostate cancer: a dual perspective on early detection and advanced disease management","volume":"17","author":"Kopytov","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.suc.2026.03.008_bib67","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/s41467-024-45475-w","article-title":"Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer","volume":"15","author":"Fonseca","year":"2024","journal-title":"Nat Commun"},{"issue":"15","key":"10.1016\/j.suc.2026.03.008_bib68","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1158\/1078-0432.CCR-22-2998","article-title":"Early On-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer","volume":"29","author":"Tolmeijer","year":"2023","journal-title":"Clin Cancer Res"}],"container-title":["Surgical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039610926000368?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039610926000368?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:56:36Z","timestamp":1786035396000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039610926000368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0039610926000368"],"URL":"https:\/\/doi.org\/10.1016\/j.suc.2026.03.008","relation":{},"ISSN":["0039-6109"],"issn-type":[{"value":"0039-6109","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetics and Screening in Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Surgical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.suc.2026.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}